Oni, a San Diego, CA- and Oxford, UK-based biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, closed a $75m Series B financing.
The round was led by ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures and private investors, including Paul Conley, as well as existing investors, including Oxford Science Enterprises.
The company intends to use the funds to grow its commercial and R&D teams in the US and Asia,
- driving technology adoption in those geographies, and
- expanding its portfolio of consumables and cloud-based software apps.
Founded in 2016 as a spin-out of Oxford University and led by Bo Jing, CEO, Oni has developed the Nanoimager, a desktop, super-resolution, single-molecule imaging platform capable of visualizing and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution. The first two applications are in the space of extracellular vesicles and cell therapy, especially chimeric antigen T-cell (CAR-T) therapy.
Together with founder & CEO, Bo Jing, the team now comprises:
· Tyler Ralston, Ph.D., Chief Technology Officer – previously at Butterfly Network and Tesseract Health
· Christine Nishiyama, Vice President of Operations – previously at Berkeley Lights
· Don O’Neil, MBA, Vice President of Commercial Operations – previously at Gemini Bio
· Ricardo Bastos, Ph.D., Director of Business Development – who started his career at ONI
· Sophia Mowla, Chief Growth Officer – previously at True Search
Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners, and Shaun Rodriguez, Director of Life Science Research at Casdin Capital, have joined ONI’s board of directors in addition to Patrick Finn, Chief Commercial Officer at Twist Bioscience who joined in 2021.